Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Recurrent Pyogenic Cholangitis Workup

  • Author: Praveen K Roy, MD, AGAF; Chief Editor: Julian Katz, MD  more...
 
Updated: Jul 24, 2015
 

Laboratory Studies

Diagnostic testing in the workup of recurrent pyogenic cholangitis includes the following:

  • Complete blood count: A leukocytosis with a left shift is typical in patients with pyogenic cholangitis.
  • Liver function tests: Aminotransferases, serum bilirubin, and alkaline phosphatase typically are elevated in patients with RPC. As with most biliary problems, no predictive or discriminant levels are available to help guide a diagnosis. In other words, any abnormal values in the appropriate clinical setting should prompt a suspicion of RPC, regardless of the degree of liver function test abnormality.
  • Prothrombin time: This may become prolonged if persistent cholestasis with consequent fat malabsorption and vitamin K deficiency is present. This is important to exclude because hypoprothrombinemia can impact the safety of invasive procedures and is easily correctible with parenteral vitamin K in this setting.
  • Blood cultures: These are mandatory because many patients are bacteremic. The blood culture results often help guide antibiotic choice.
  • Ova and parasites: Clonorchis infection frequently is associated with RPC and should be sought and treated when present.
Next

Imaging Studies

Noninvasive imaging studies

Noninvasive imaging studies include transabdominal ultrasonography, computed tomography (CT) scanning, and magnetic resonance cholangiopancreatography (MRCP).

Ultrasonography is the preferred initial test during the primary workup. This imaging modality may demonstrate segmental biliary dilatation, hepatolithiasis, and liver abscesses, if present. Ultrasonography findings often determines the choice of supplemental axial imaging techniques.

CT scanning may demonstrate centrally dilated bile ducts with peripheral tapering. Cholangiohepatitis has a predilection for the left lobe of the liver, and predominantly left-sided findings should prompt consideration of this diagnosis in patients from endemic areas. Other potential findings on CT scans include bile duct stones and pyogenic liver abscesses.

The role of MRCP in the investigation of biliary disease continues to evolve in spite of the poor availability of magnetic resonance imaging (MRI) facilities in many regions of the world where RPC is endemic. MRI produces axial images and can be performed to evaluate the portal and hepatic venous system. Note the following:

  • MR cholangiography may quickly replace endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography as the imaging modality of choice for delineating the biliary tree.
  • In a recent study of 45 patients with RPC who underwent direct cholangiography and MR cholangiography, MR cholangiography demonstrated 100% of all dilated segments, 96% of all strictures, and 98% of all calculi, whereas direct cholangiography demonstrated significantly less, reportedly 44% of all strictures and 45% of all calculi.
  • The role of MRCP is complementary to direct cholangiography, as MRCP, at present, does not offer any therapeutic opportunities. [4, 5, 6]

MRI has been effective in differential diagnosis of malignant versus benign hepatic masses.[7]

Invasive imaging techniques

Cholangiography in the management of RPC is pivotal.

The choice of endoscopic (ie, ERCP) versus percutaneous cholangiography hinges on the patient's anatomy and general health status and on the availability of local expertise.

Very often, a combination of both techniques is necessary to achieve complete ductal clearance of stones and to ensure that drainage of the biliary tree has been optimized.

Previous
 
 
Contributor Information and Disclosures
Author

Praveen K Roy, MD, AGAF Chief of Gastroenterology, Presbyterian Hospital; Medical Director of Endoscopy, Presbyterian Medical Group; Adjunct Associate Research Scientist, Lovelace Respiratory Research Institute

Praveen K Roy, MD, AGAF is a member of the following medical societies: American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Coauthor(s)

Rajan Kanth, MD Hospitalist, Ministry Saint Joseph’s Hospital

Rajan Kanth, MD is a member of the following medical societies: American College of Physicians, Society of Hospital Medicine, Nepal Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Additional Contributors

Anil Minocha, MD, FACP, FACG, AGAF, CPNSS Professor of Medicine, Director of Digestive Diseases, Medical Director of Nutrition Support, Medical Director of Gastrointestinal Endoscopy, Internal Medicine Department, University of Mississippi Medical Center; Clinical Professor, University of Mississippi School of Pharmacy

Anil Minocha, MD, FACP, FACG, AGAF, CPNSS is a member of the following medical societies: American Academy of Clinical Toxicology, American Society for Gastrointestinal Endoscopy, American Federation for Clinical Research, American Association for the Study of Liver Diseases, American College of Forensic Examiners Institute, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Patrick I Okolo III, MD, MPH, and previous coauthor Sam Yoselevitz, MD, to the development and writing of this article.

References
  1. Koklu S, Akkus MA, Tas A, et al. Recurrent pyogenic cholangitis in a case with congenital biliary anomaly. Ann Hepatol. 2012 Mar-Apr. 11(2):268-71. [Medline].

  2. Jeyarajah DR. Recurrent pyogenic cholangitis. Curr Treat Options Gastroenterol. 2004 Apr. 7(2):91-98. [Medline].

  3. Bass N. Sclerosing Cholangitis and Recurrent Pyogenic Cholangitis. Feldman M, Scharschmidt B, Slesinger M, eds. Gastrointestinal and Liver Disease. Philadelphia, Pa: WB Saunders; 1993. Vol 1: 1006-25.

  4. Chan FL, Chan JK, Leong LL. Modern imaging in the evaluation of hepatolithiasis. Hepatogastroenterology. 1997 Mar-Apr. 44(14):358-69. [Medline].

  5. Jain M, Agarwal A. MRCP findings in recurrent pyogenic cholangitis. Eur J Radiol. 2008 Apr. 66(1):79-83. [Medline].

  6. Heffernan EJ, Geoghegan T, Munk PL, Ho SG, Harris AC. Recurrent pyogenic cholangitis: from imaging to intervention. AJR Am J Roentgenol. 2009 Jan. 192(1):W28-35. [Medline]. [Full Text].

  7. Eun HW, Kim JH, Hong SS, Kim YJ. Malignant versus benign hepatic masses in patients with recurrent pyogenic cholangitis: MR differential diagnosis. Abdom Imaging. 2012 Oct. 37(5):767-74. [Medline].

  8. Al-Sukhni W, Gallinger S, Pratzer A, Wei A, Ho CS, Kortan P, et al. Recurrent pyogenic cholangitis with hepatolithiasis--the role of surgical therapy in North America. J Gastrointest Surg. 2008 Mar. 12(3):496-503. [Medline].

  9. Tsui WM, Chan YK, Wong CT, Lo YF, Yeung YW, Lee YW. Hepatolithiasis and the syndrome of recurrent pyogenic cholangitis: clinical, radiologic, and pathologic features. Semin Liver Dis. 2011 Feb. 31(1):33-48. [Medline].

  10. Lee KF, Chong CN, Ng D, et al. Outcome of surgical treatment for recurrent pyogenic cholangitis: a single-centre study. HPB (Oxford). 2009. 11(1):75-80. [Medline]. [Full Text].

  11. Afagh A, Pancu D. Radiologic findings in recurrent pyogenic cholangitis. J Emerg Med. 2004 Apr. 26(3):343-6. [Medline].

  12. American College of Surgeons. Surgical Education and Self-assessment Program (SESAP). Recurrent pyogenic cholangitis. Can J Surg. 2004 Apr. 47(2):121. [Medline].

  13. Carmona RH, Crass RA, Lim RC Jr, Trunkey DD. Oriental cholangitis. Am J Surg. 1984 Jul. 148(1):117-24. [Medline].

  14. Chen MF, Jan YY, Wang CS, et al. A reappraisal of cholangiocarcinoma in patient with hepatolithiasis. Cancer. 1993 Apr 15. 71(8):2461-5. [Medline].

  15. Chen PH, Lo HW, Wang CS, et al. Cholangiocarcinoma in hepatolithiasis. J Clin Gastroenterol. 1984 Dec. 6(6):539-47. [Medline].

  16. Cheng YF, Lee TY, Sheen-Chen SM, Huang TL, Chen TY. Treatment of complicated hepatolithiasis with intrahepatic biliary stricture by ductal dilatation and stenting: long-term results. World J Surg. 2000 Jun. 24(6):712-6. [Medline].

  17. Chijiiwa K, Yamashita H, Yoshida J, Kuroki S, Tanaka M. Current management and long-term prognosis of hepatolithiasis. Arch Surg. 1995 Feb. 130(2):194-7. [Medline].

  18. Cosenza CA, Durazo F, Stain SC, Jabbour N, Selby RR. Current management of recurrent pyogenic cholangitis. Am Surg. 1999 Oct. 65(10):939-43. [Medline].

  19. Digby KH. Common-duct stones of liver origin. Br J Surg. 1930. 17:578-91.

  20. Koga A, Ichimiya H, Yamaguchi K, Miyazaki K, Nakayama F. Hepatolithiasis associated with cholangiocarcinoma. Possible etiologic significance. Cancer. 1985 Jun 15. 55(12):2826-9. [Medline].

  21. Lam SK. A study of endoscopic sphincterotomy in recurrent pyogenic cholangitis. Br J Surg. 1984 Apr. 71(4):262-6. [Medline].

  22. Lee SK, Seo DW, Myung SJ, et al. Percutaneous transhepatic cholangioscopic treatment for hepatolithiasis: an evaluation of long-term results and risk factors for recurrence. Gastrointest Endosc. 2001 Mar. 53(3):318-23. [Medline].

  23. Lee Y, Lee BH, Park JH, Suh CH. Balloon dilatation of intrahepatic biliary strictures for percutaneous extraction of residual intrahepatic stones. Cardiovasc Intervent Radiol. 1991 Mar-Apr. 14(2):102-5. [Medline].

  24. Lim JH. Oriental cholangiohepatitis: pathologic, clinical, and radiologic features. AJR Am J Roentgenol. 1991 Jul. 157(1):1-8. [Medline].

  25. Min HK. Clonorchis sinensis: pathogenesis and clinical features of infection. Arzneimittelforschung. 1984. 34(9B):1151-3. [Medline].

  26. Nakanuma Y, Terada T, Tanaka Y, Ohta G. Are hepatolithiasis and cholangiocarcinoma aetiologically related? A morphological study of 12 cases of hepatolithiasis associated with cholangiocarcinoma. Virchows Arch A Pathol Anat Histopathol. 1985. 406(1):45-58. [Medline].

  27. Ng WT. Pathogenesis of acute cholecystitis and recurrent pyogenic cholangitis. Surg Laparosc Endosc Percutan Tech. 2004 Aug. 14(4):240-1. [Medline].

  28. Saing H, Chan KL, Mya GH, Cheng W, Fan ST, Chan FL. Cutaneous stoma in the roux limb of hepaticojejunostomy (hepaticocutaneous jejunostomy): useful access for intrahepatic stone extraction. J Pediatr Surg. 1996 Feb. 31(2):247-50. [Medline].

  29. Schulman A. Intrahepatic biliary stones: imaging features and a possible relationship with ascaris lumbricoides. Clin Radiol. 1993 May. 47(5):325-32. [Medline].

  30. Sheen-Chen S, Chen W, Eng H, et al. Bacteriology and antimicrobial choice in hepatolithiasis. Am J Infect Control. 2000 Aug. 28(4):298-301. [Medline].

  31. Sperling RM, Koch J, Sandhu JS, Cello JP. Recurrent pyogenic cholangitis in Asian immigrants to the United States: natural history and role of therapeutic ERCP. Dig Dis Sci. 1997 Apr. 42(4):865-71. [Medline].

  32. Stain SC, Incarbone R, Guthrie CR, et al. Surgical treatment of recurrent pyogenic cholangitis. Arch Surg. 1995 May. 130(5):527-32; discussion 532-3. [Medline].

  33. Tanaka M, Ikeda S, Ogawa Y, et al. Divergent effects of endoscopic sphincterotomy on the long-term outcome of hepatolithiasis. Gastrointest Endosc. 1996 Jan. 43(1):33-7. [Medline].

  34. Tang CN, Tai CK, Ha JP, Siu WT, Tsui KK, Li MK. Laparoscopy versus open left lateral segmentectomy for recurrent pyogenic cholangitis. Surg Endosc. 2005 Sep. 19(9):1232-6. [Medline].

  35. Tang CN, Tai CK, Siu WT, Ha JP, Tsui KK, Li MK. Laparoscopic treatment of recurrent pyogenic cholangitis. J Hepatobiliary Pancreat Surg. 2005. 12(3):243-8. [Medline].

  36. Wong WT, Teoh-Chan CH, Huang CT, Cheng FC, Ong GB. The bacteriology of recurrent pyogenic cholangitis and associated diseases. J Hyg (Lond). 1981 Dec. 87(3):407-12. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.